NASDAQ$CYTK
Cytokinetics Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year 2020.
Cytokinetics reported a net loss of $43.9 million for the fourth quarter of 2020, with revenues of $6.7 million. The company's cash, cash equivalents, and investments totaled $501.0 million at the end of the year, providing more than two years of cash runway.
- Presented results of GALACTIC-HF, demonstrating a positive effect on the primary composite endpoint.
- Planned to discuss GALACTIC-HF results with the FDA to inform a potential registration path.
- Progressed REDWOOD-HCM to Cohort 2 after a positive interim analysis and completed enrollment.
- Provided 2021 financial guidance, anticipating revenue between $23 to $28 million.
Headline financials
Revenue & EPS history
Cytokinetics · Revenue · Quarterly
$6.72M
Forward guidance
The company anticipates revenue will be in the range of $23 to $28 million, operating expenses will be in the range of $195 to $205 million, and net cash utilization will be approximately $160 to 170 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+0.4%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+2.2%
Avg return
30 days after
49%
32 / 65 earnings
Positive
+21.4%
Q4 2014
Best reaction
-17.7%
Q2 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +16.8% | +16.5% | +9.5% | |
| Q4 2025 | -10.3% | -12.4% | -10.8% | |
| Q3 2025 | +1.9% | +12.4% | +10.9% | |
| Q1 2025 | -2.8% | -5.4% | -4.9% | |
| Q4 2024 | -3.1% | -7.5% | -9.0% | |
| Q3 2024 | +6.3% | +11.6% | -3.0% | |
| Q2 2024 | +8.9% | +9.5% | +5.6% | |
| Q1 2024 | -1.9% | -11.3% | -19.1% | |
| Q4 2023 | -7.5% | -6.4% | -11.3% | |
| Q3 2023 | +3.5% | +2.1% | -4.4% | |
| Q2 2023 | +6.8% | +2.8% | +15.8% | |
| Q1 2023 | +0.3% | -1.3% | -1.8% | |
| Q4 2022 | -8.7% | -9.8% | -18.8% | |
| Q3 2022 | -9.8% | -8.6% | -3.3% | |
| Q2 2022 | +21.0% | +22.5% | +26.2% | |
| Q1 2022 | +0.9% | -12.6% | +7.2% | |
| Q4 2021 | +11.7% | +14.7% | +16.3% | |
| Q3 2021 | +12.4% | +18.2% | +2.4% | |
| Q2 2021 | +7.8% | +8.2% | +10.0% | |
| Q1 2021 | +2.8% | +0.8% | -13.4% | |
| Q4 2020 | -9.7% | -6.4% | +15.0% | |
| Q3 2020 | +5.1% | +0.8% | +2.4% | |
| Q2 2020 | -2.8% | -4.7% | +2.2% | |
| Q1 2020 | -4.2% | +27.8% | +23.3% | |
| Q4 2019 | +4.4% | +1.1% | -15.4% | |
| Q3 2019 | -5.5% | -6.5% | -18.3% | |
| Q2 2019 | +1.1% | -2.0% | +5.5% | |
| Q1 2019 | +12.6% | +16.7% | +10.4% | |
| Q4 2018 | -0.8% | -2.7% | +19.2% | |
| Q3 2018 | +10.6% | +5.7% | +17.5% | |
| Q2 2018 | -5.7% | -7.0% | -9.5% | |
| Q1 2018 | +19.3% | +14.5% | +21.4% | |
| Q4 2017 | -10.8% | -13.9% | -2.8% | |
| Q3 2017 | +6.7% | +2.2% | -43.1% | |
| Q2 2017 | -5.6% | -11.2% | +3.1% | |
| Q1 2017 | -3.0% | -7.7% | -16.6% | |
| Q4 2016 | -1.7% | -9.2% | +8.3% | |
| Q3 2016 | +9.3% | +6.6% | +39.7% | |
| Q2 2016 | +7.3% | +12.8% | +18.1% | |
| Q1 2016 | +3.3% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | +13.3% | — | — | |
| Q2 2015 | -17.7% | — | — | |
| Q1 2015 | -15.7% | — | — | |
| Q4 2014 | +21.4% | — | — | |
| Q3 2014 | -1.0% | — | — | |
| Q2 2014 | -1.2% | — | — | |
| Q1 2014 | -9.5% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | -7.2% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q4 2012 | -1.0% | — | — | |
| Q3 2012 | -1.6% | — | — | |
| Q2 2012 | +6.3% | — | — | |
| Q1 2012 | -4.0% | — | — | |
| Q4 2009 | +0.8% | — | — | |
| Q4 2011 | +0.8% | — | — | |
| Q3 2011 | +3.5% | — | — | |
| Q2 2011 | -14.0% | — | — | |
| Q4 2010 | -14.0% | — | — | |
| Q1 2011 | +2.9% | — | — | |
| Q3 2010 | -4.0% | — | — | |
| Q2 2010 | -14.3% | — | — | |
| Q1 2010 | +0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro